Shots:
C4XD is eligible to receive ~$16M pre-clinical milestones fees for the first clinical trial incl. $2M up front and is also eligible to receive $385.8M in clinical development and commercial milestones along with royalties
AstraZeneca will be responsible to develop and commercialize an oral therapy for the treatment of inflammatory and respiratory diseases with an initial focus on COPD
The agreement adds new assets to AstraZeneca’s portfolio & targets underlying disease drivers to modify the course of the diseases. The agreement further supports C4XD’s scientific expertise and strategy through the third deal with the pharmaceutical company
Ref: Globenewswire | Image: AstraZeneca
